Utility of the low-accelerating-dose regimen in 182 liver recipients with recurrent hepatitis C virus

Table 3 Univariate analysis

Factors associated with SVR	SVR (%)	P value
HCV genotype 1 vs non-1	29 vs 71	< 0.0001
HCV viral load < 1 million vs≥ 1 million IU/mL	54 vs 33	0.009
Recipient IL28B-CC vs non-CC	55 vs 34	0.03
Paired IL28b recipient CC and donor non-CC vs other recipient and donor combinations	72 vs 36	0.007
Pre-treatment total bilirubin < 1.5 mg vs≥ 1.5 mg	44 vs 25	0.02
Pre-treatment ALP < 150 vs≥ 150	44 vs 29	0.04
Treatment duration ≥ 48 wk vs < 48 wk	45 vs 27	0.02
Peak RBV dose ≥ 800 mg vs < 800 mg	44 vs 25	0.02
Administration of MMF vs No MMF	30 vs 43	0.09
RVR vs no RVR	34 vs 66	0.0006
EVR vs no EVR	85 vs 15	< 0.0001
Week 8 HCV RNA undetectable vs detectable	72 vs 20	< 0.0001
Donor age ≤ 40 vs > 40	58 vs 29	0.0002
Matched recipient and donor ethnicity vs unmatched	46 vs 33	0.09
Mismatched CMV status (D+/R-) vs other combinations	54 vs 35	0.04
Pre-treatment fibrosis stage 0-2 vs 3-4	43 vs 26	0.08
Factors associated with patient survival	10-year survival (%)
Week 8 HCV RNA undetectable vs detectable	71 vs 44	0.003
Week 12 HCV RNA undetectable vs detectable	73 vs 44	< 0.001
Pre-treatment fibrosis stage 0-2 vs 3-4	70 vs 31	0.004
Pre-treatment ALP < 150 vs≥ 150	67 vs 42	< 0.001
Pre-treatment total bilirubin < 1.5 mg vs≥ 1.5 mg	62 vs 46	< 0.001
Pre-treatment creatinine < 2 vs≥ 2	61 vs 0	< 0.001

HCV: Hepatitis C virus; ALP: Alkaline phosphatase; RBV: Ribavirin.